We provide you with 20 years of free, institutional-grade data for ACHL stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of ACHL. Explore the full financial landscape of ACHL stock.
| Reported Date | CIK | Ticker | Type |
|---|
Achilles Therapeutics plc(NASDAQ:ACHL) 
Achilles Therapeutics Plc, a clinical stage immuno-oncology biopharmaceutical company, develops precision T cell therapies to treat various types of solid tumors. The company's lead product candidates include CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-sma...
The information provided in this report about ACHL stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.